Please assess the completion status of the following clinical trial:

Trial Title: Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* End-stage renal disease (ESRD) without prior sensitization (defined as Panel Reactive Antibody \[PRA\] greater than 20%) within the 60 days prior to transplant as measured by cytotoxicity assays, ELISA, and flow cytometry;~* Undergoing a first or second transplant;~* Receiving a transplant from a living related donor who is ABO (blood type) compatible and haploidentical (3, 4, or 5 antigen match by serologic typing);~* Cardiac ejection fraction greater than 40%;~* Forced expiratory volume (FEV1) greater than 50%;~* Liver function tests, bilirubin, and coagulation studies less than 2 X normal;~* White blood cells greater than 2000/mm\^3; abd~* Platelets greater than 100,000/mm\^3~Exclusion Criteria:~* Positive donor lymphocyte cross-match;~* HIV-1 infected;~* Positive hepatitis B surface antigen (HbsAg);~* Hepatitis C virus infected;~* History of cancer;~* Prior dose-limiting radiation therapy;~* Pregnant, breastfeeding, or planning pregnancy within the time frame of the study;~* Enrolled in another investigational drug study within 30 days prior to study entry; or~* Receiving maintenance immunosuppression within 3 months before the conditioning regimen begins

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Conditioning Regimen (Type: EXPERIMENTAL): Cyclophosphamide intravenously (IV) on days -5 and -4 with respect to transplantation; MEDI-507 on days -1, 0, and 1 (after a test dose of 0.1 mg per kg on day -2); and cyclosporine A IV and thymic irradiation on day -1. Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow. Oral cyclosporine A was administered daily postoperatively, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months.~Amendment applicable to the 4th and 5th participant: rituximab on days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).